Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9130238 | 1.00 | SMPD1 (0.50) | SMPD1SLC6A5LPAR3LPAR1LPAR2 | |
| SCHEMBL3332099 | 1.00 | SMPD1 (0.50) | SMPD1SLC6A5LPAR3LPAR1LPAR2 | |
| SCHEMBL27542771 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL744377 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL5481597 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL27835477 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL596695 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL1044719 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL27699114 | 0.91 | SMPD1 (0.59) | SMPD1PTPN1S1PR1S1PR4S1PR3 | |
| SCHEMBL9026174 | 0.90 | SMPD1 (0.49) | SMPD1LPAR3LPAR1LPAR2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1876900-A4 | PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV COLUMBIA (US) | 2009-06-24 | — | — | EP | claimed |
| CN-101340918-A | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2009-01-07 | — | — | CN | claimed |
| EP-1876900-A2 | PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | The Trustees of Columbia University in the City of New York (US) | 2008-01-16 | — | — | EP | claimed |
| WO-2006118630-A2 | PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-11-09 | — | — | WO | claimed |
| CN-117355333-A | Combination comprising anti-TM 4SF1 antibody and immunotherapeutic agent and method of use thereof | 安吉克公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-112601583-A | CARTyrin compositions and methods of use | 波赛达治疗公司 | 2021-04-02 | — | — | CN | disclosed |
| CN-112218885-A | VCAR compositions and methods of use | 波赛达治疗公司 | 2021-01-12 | — | — | CN | disclosed |
| CN-111727256-A | Compositions and methods for Chimeric Ligand Receptor (CLR) -mediated conditional gene expression | 波赛达治疗公司 | 2020-09-29 | — | — | CN | disclosed |
| CN-106795550-A | Genomic rearrangements associated with prostate cancer and methods of using the same | 促进军事医学的亨利·M·杰克逊基金会公司 | 2017-05-31 | — | — | CN | disclosed |
| CN-101340918-B | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof | AETERNA ZENTARIS GMBH | 2012-10-03 | — | — | CN | disclosed |
| CN-101340918-A | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2009-01-07 | — | — | CN | disclosed |
| US-20040247659-A1 | (Ester)-lysolecithins in liposomes | PROFESSOR DR. JOERG EIBL (DE) | 2004-12-09 | — | — | US | disclosed |
| US-20030083313-A1 | Treatment of breast cancer with a liposome mixture comprising an antineoplastic alkylphospholipid and water- or lipid-soluble antiestrogen agents | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2003-05-01 | — | — | US | disclosed |
| US-5436234-A | Treatment of protozoal and fungal diseases, autoimmune diseases and bone marrow damage | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG (DE) | 1995-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040247659-A1 | (Ester)-lysolecithins in liposomes | LIPA, LCLAT1, CETP | SMPD1 75/4885SLC6A5 1531/4885LPAR3 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.